Cargando…

Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer

BACKGROUND: Treatment of differentiated thyroid cancer usually consists of a total thyroidectomy followed by one or several courses of radioiodine ((131)I). (131)I is known to have deleterious effects on radiation sensitive tissues and irradiation to the testes has been shown after its administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Esquerré-Lamare, Camille, Isus, François, Moinard, Nathalie, Bujan, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522285/
https://www.ncbi.nlm.nih.gov/pubmed/26236480
http://dx.doi.org/10.1186/s12610-015-0024-1
_version_ 1782383936101416960
author Esquerré-Lamare, Camille
Isus, François
Moinard, Nathalie
Bujan, Louis
author_facet Esquerré-Lamare, Camille
Isus, François
Moinard, Nathalie
Bujan, Louis
author_sort Esquerré-Lamare, Camille
collection PubMed
description BACKGROUND: Treatment of differentiated thyroid cancer usually consists of a total thyroidectomy followed by one or several courses of radioiodine ((131)I). (131)I is known to have deleterious effects on radiation sensitive tissues and irradiation to the testes has been shown after its administration. We investigated effects of such treatment on sperm DNA in a patient with differentiated thyroid carcinoma. METHODS: The patient, a 32-year-old male with differentiated thyroid carcinoma treated by total thyroidectomy and radioiodine therapy, performed 6 semen samples in total, 3 for sperm banking and 3 for semen exploration, that were analysed for classic semen parameters. DNA integrity was analysed by flow cytometry: sperm DNA fragmentation index (DFI) and high DNA stainability (HDS) were analyzed by sperm chromatin structure assay, DNA fragmentation was analyzed by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. RESULTS: Moderate oligozoospermia was observed as early as 3 months after a first dose of (131)I and became severe at 5 months. Total sperm count was reduced up to 12 months after the second dose of (131)I. Sperm DFI was increased 3.25 months after the first dose of (131)I. All parameters returned to normal values 28 months after the second (131)I dose. CONCLUSIONS: Treatment with (131)I induces alterations in sperm chromatin as well as in sperm parameters a short time (3 months) after a first dose of (131)I with persistence of sperm alterations until 12 months after a second dose. Sperm banking should be recommended before treatment.
format Online
Article
Text
id pubmed-4522285
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45222852015-08-03 Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer Esquerré-Lamare, Camille Isus, François Moinard, Nathalie Bujan, Louis Basic Clin Androl Research Article BACKGROUND: Treatment of differentiated thyroid cancer usually consists of a total thyroidectomy followed by one or several courses of radioiodine ((131)I). (131)I is known to have deleterious effects on radiation sensitive tissues and irradiation to the testes has been shown after its administration. We investigated effects of such treatment on sperm DNA in a patient with differentiated thyroid carcinoma. METHODS: The patient, a 32-year-old male with differentiated thyroid carcinoma treated by total thyroidectomy and radioiodine therapy, performed 6 semen samples in total, 3 for sperm banking and 3 for semen exploration, that were analysed for classic semen parameters. DNA integrity was analysed by flow cytometry: sperm DNA fragmentation index (DFI) and high DNA stainability (HDS) were analyzed by sperm chromatin structure assay, DNA fragmentation was analyzed by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. RESULTS: Moderate oligozoospermia was observed as early as 3 months after a first dose of (131)I and became severe at 5 months. Total sperm count was reduced up to 12 months after the second dose of (131)I. Sperm DFI was increased 3.25 months after the first dose of (131)I. All parameters returned to normal values 28 months after the second (131)I dose. CONCLUSIONS: Treatment with (131)I induces alterations in sperm chromatin as well as in sperm parameters a short time (3 months) after a first dose of (131)I with persistence of sperm alterations until 12 months after a second dose. Sperm banking should be recommended before treatment. BioMed Central 2015-08-02 /pmc/articles/PMC4522285/ /pubmed/26236480 http://dx.doi.org/10.1186/s12610-015-0024-1 Text en © Esquerré-Lamare et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Esquerré-Lamare, Camille
Isus, François
Moinard, Nathalie
Bujan, Louis
Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
title Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
title_full Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
title_fullStr Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
title_full_unstemmed Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
title_short Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
title_sort sperm dna fragmentation after radioiodine treatment for differentiated thyroid cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522285/
https://www.ncbi.nlm.nih.gov/pubmed/26236480
http://dx.doi.org/10.1186/s12610-015-0024-1
work_keys_str_mv AT esquerrelamarecamille spermdnafragmentationafterradioiodinetreatmentfordifferentiatedthyroidcancer
AT isusfrancois spermdnafragmentationafterradioiodinetreatmentfordifferentiatedthyroidcancer
AT moinardnathalie spermdnafragmentationafterradioiodinetreatmentfordifferentiatedthyroidcancer
AT bujanlouis spermdnafragmentationafterradioiodinetreatmentfordifferentiatedthyroidcancer